ArticleMikrochimica acta2025
Fluorescence origami paper-based analytical device based on strand displacement assay for SARS-CoV-2 cDNA detection.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A fluorescence origami paper-based analytical device (Flu-oPAD) based on a strand displacement assay as a point-of-care testing (POCT) sensing platform for DNA detection is presented. This device facilitates multiple steps in a single device, including sample loading, incubation, and washing. The detection zone was immobilized with a 6-FAM-modified probe (F-probe), which formed a complex with a BHQ1-modified probe (Q-probe) to minimize background signals. In the presence of target DNA, hybridization with the F-probe releases the Q-probe, resulting in a fluorescence response proportional to the target DNA concentration. The sensor exhibits good selectivity for target DNA, with a linearity range from 0.1 nM to 10 μM and an experimental detection limit of 0.1 nM, completing all procedures within 15 min. The real-world applicability is demonstrated by successfully detecting complementary DNA (cDNA) from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a cause of the COVID-19 pandemic. This study further introduces a multi-array Flu-oPAD for simultaneous detection of SARS-CoV-2 ORF1ab, N, and E gene cDNAs. This multi-array Flu-oPAD is applied to nasopharyngeal swab samples, showing good agreement with the standard RT-PCR method. Overall, the developed Flu-oPAD has shown great potential as an effective POCT tool for DNA screening. It offers simplicity, portability, accessibility, and cost-effectiveness, offering its potential impact on addressing pressing healthcare needs.
Indexed as
Identifiers
40434444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.